ROCKVILLE, MD, USA and OSAKA, Japan I September 29, 2014 I MacroGenics, Inc. (MGNX) and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into a collaboration agreement to develop and commercialize up to four product candidates. These four research programs are in addition to MGD010, which was the subject of a prior agreement announced in May 2014. Each of these product candidates will be directed against jointly selected pairs of molecular targets and incorporate MacroGenics’ Dual-Affinity Re-Targeting (DART(R)) proprietary platform.
“We are very pleased to increase our investment in finding biotherapeutic treatments for critical diseases by expanding our collaboration with MacroGenics. The breadth of our alliance with MacroGenics underscores our confidence in their research and development capabilities, as well as the robustness and versatility of their bi-specific DART platform,” said Tetsuyuki Maruyama, Ph.D., General Manager of the Pharmaceutical Research Division at Takeda. “We look forward to progressing the development of multiple product candidates under our strategic collaboration with MacroGenics.”
Under the terms of this second agreement, Takeda receives an option to obtain an exclusive worldwide license for each of the four product candidates and will fund all research and development activities related to the programs, including reimbursement of MacroGenics’ expenses. Assuming successful development and commercialization by Takeda, MacroGenics could receive up to an additional approximately $400 million in program initiation, pre-clinical, clinical, regulatory and commercialization milestone payments for each of four potential product candidates. If commercialized, MacroGenics would receive double-digit royalties on any global net sales and has the option to co-promote each product candidate with Takeda in the United States. Finally, MacroGenics may elect to fund a portion of Phase 3 clinical development of each product candidate in exchange for a North American profit share.
“We are delighted to enter our sixth DART collaboration with a major pharmaceutical company that has proven global development and commercialization capabilities,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “Building upon MGD010, I am very excited about the opportunity to expand our collaboration in the autoimmune area with an existing partner that has demonstrated clear support in enabling us to further broaden and accelerate our pipeline of innovative DART-based product candidates.”
Background on DART Platform
MacroGenics’ Dual-Affinity Re-Targeting (DART(R)) platform enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure. The Company has created over 100 DART molecules which have been configured for the potential treatment of cancer, autoimmune disorders and infectious disease. These DART molecules can be tailored for either short or prolonged pharmacokinetics and have demonstrated good stability and attractive manufacturability. The Company has advanced its first DART molecule, MGD006, into clinical development and expects to advance its second DART molecule, MGD007, into clinical development in the second half of 2014.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which are designed to improve upon the performance of monoclonal antibodies and antibody-derived molecules. The combination of MacroGenics’ technology platforms and antibody engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. Additional information about MacroGenics can be found on its corporate website at www.MacroGenics.com. MacroGenics and DART are registered trademarks of MacroGenics, Inc.
SOURCE: MacroGenics
Post Views: 36
ROCKVILLE, MD, USA and OSAKA, Japan I September 29, 2014 I MacroGenics, Inc. (MGNX) and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into a collaboration agreement to develop and commercialize up to four product candidates. These four research programs are in addition to MGD010, which was the subject of a prior agreement announced in May 2014. Each of these product candidates will be directed against jointly selected pairs of molecular targets and incorporate MacroGenics’ Dual-Affinity Re-Targeting (DART(R)) proprietary platform.
“We are very pleased to increase our investment in finding biotherapeutic treatments for critical diseases by expanding our collaboration with MacroGenics. The breadth of our alliance with MacroGenics underscores our confidence in their research and development capabilities, as well as the robustness and versatility of their bi-specific DART platform,” said Tetsuyuki Maruyama, Ph.D., General Manager of the Pharmaceutical Research Division at Takeda. “We look forward to progressing the development of multiple product candidates under our strategic collaboration with MacroGenics.”
Under the terms of this second agreement, Takeda receives an option to obtain an exclusive worldwide license for each of the four product candidates and will fund all research and development activities related to the programs, including reimbursement of MacroGenics’ expenses. Assuming successful development and commercialization by Takeda, MacroGenics could receive up to an additional approximately $400 million in program initiation, pre-clinical, clinical, regulatory and commercialization milestone payments for each of four potential product candidates. If commercialized, MacroGenics would receive double-digit royalties on any global net sales and has the option to co-promote each product candidate with Takeda in the United States. Finally, MacroGenics may elect to fund a portion of Phase 3 clinical development of each product candidate in exchange for a North American profit share.
“We are delighted to enter our sixth DART collaboration with a major pharmaceutical company that has proven global development and commercialization capabilities,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “Building upon MGD010, I am very excited about the opportunity to expand our collaboration in the autoimmune area with an existing partner that has demonstrated clear support in enabling us to further broaden and accelerate our pipeline of innovative DART-based product candidates.”
Background on DART Platform
MacroGenics’ Dual-Affinity Re-Targeting (DART(R)) platform enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure. The Company has created over 100 DART molecules which have been configured for the potential treatment of cancer, autoimmune disorders and infectious disease. These DART molecules can be tailored for either short or prolonged pharmacokinetics and have demonstrated good stability and attractive manufacturability. The Company has advanced its first DART molecule, MGD006, into clinical development and expects to advance its second DART molecule, MGD007, into clinical development in the second half of 2014.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which are designed to improve upon the performance of monoclonal antibodies and antibody-derived molecules. The combination of MacroGenics’ technology platforms and antibody engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. Additional information about MacroGenics can be found on its corporate website at www.MacroGenics.com. MacroGenics and DART are registered trademarks of MacroGenics, Inc.
SOURCE: MacroGenics
Post Views: 36
